CLINICAL TRIAL SUMMARY

MDACC Study No:2011-0467 (clinicaltrials.gov NCT No: NCT01485536)
Title:A Phase II Study of the HSP90 Inhibitor AUY922 in Patients with Relapsed and Refractory Lymphoma
Principal Investigator:Yasuhiro Oki
Treatment Agent:AUY922
Study Status:Closed
Study Description:Unavailable

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:AUY922
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Supported by Novartis
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Yasuhiro Oki
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults